Skip to content

Valneva

  • Über uns
    Über uns Advancing vaccines for better lives Mehr lesen
    • Unsere Strategie
    • Unsere Expertise im Bereich der Reisegesundheit
    • Unsere Verantwortung
    • Unser Team
  • Produkte
    Produkte Focusing on vaccines for infectious diseases with major unmet needs Mehr lesen
    • Japanische Enzephalitis-Impfstoff
    • Cholera-Impfstoff
    • COVID-19 Impfstoff
    • Marketing und Vertrieb
    • Produktion und Dienstleistungen
  • F&D
    F&D Dedicated to innovation in vaccine research and development Mehr lesen
    • Pipeline
    • Lyme Borreliose – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access-Richtlinie
    • Wissenschaftliche Publikationen
  • Investoren
    Investoren Mehr lesen
    • Events und Präsentationen
      • Kalender
      • Präsentationen des Unternehmens
    • Financial & Filings
      • Finanzberichte
      • SEC Filings
    • Pressemeldungen
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Vorgeschriebene Informationen
    • Aktieninformation
      • Aktienkurs
      • Analysten
      • Aktionärsstruktur
      • Delisting von der Wiener Börse
    • Hauptversammlungen
      • 2022 Kombinierte Hauptversammlung
      • June 23, 2022 Special Meeting
      • Archiv Hauptversammlungen
    • Videos und Webcasts
    • Häufig gestellte Fragen
    • Kontakt
  • Medien
    Medien Pressemeldungen, Aktuelles und Ressourcen für Medien Mehr lesen
    • Pressemeldungen
    • In den Nachrichten
    • Ressourcen für Medien
    • Medienkontakte
  • Karriere
Kontakt
  • EN
  • FR
  • | DE
Search

Pressemeldungen

July 15, 2008

VIVALIS AND INTERVET SCHERING PLOUGH ANIMAL HEALTH SIGN A LETTER OF INTENT FOR A COMMERCIAL LICENSE TO USE EBx® CELL LINE FOR A VIRAL VACCINE PRODUCTION

July 8, 2008

VIVALIS GRANTS RESEARCH LICENCE TO ACAMBIS TO EVALUATE EB66® CELL LINE FOR VIRAL VACCINES PRODUCTION

June 30, 2008

A MAJOR STEP TAKEN IN THE DEVELOPMENT OF VIVALIS: FILING OF THE EB66® CELL LINE BMF WITH THE AMERICAN FDA CONFIRMATION OF BREAKTHROUGH TECHNOLOGY STATUS FOR THE PRODUCTION OF VACCINES AND PROTEINS

June 18, 2008

VIVALIS GRANTS RIGHTS TO EBx® CELL LINE FOR TESTING IN PRODUCTION OF VIRAL VACCINES

June 3, 2008

FOLLOWING POSITIVE RESULTS VIVALIS AND BAVARIAN NORDIC EXTEND THE EBx® RESEARCH LICENCE

May 20, 2008

SOCIETE GENERALE INITIATES VIVALIS COVERAGE WITH A “BUY” RECOMMENDATION AND A PRICE TARGET OF €8.10

April 30, 2008

VIVALIS ANNOUNCES THE FILING OF ITS FIRST ANNUAL REGISTRATION DOCUMENT

April 16, 2008

Quarterly report: 1st Quarter 2008 Cash position of € 22, 8 million Objectives for 2008: Signing of 7 to 9 new EBx® licenses, including 2 commercial licenses

April 14, 2008

VIVALIS WILL PARTICIPATE IN THE SMALL CAP EVENT IN PARIS ON APRIL 21 AND 22, 2008

April 1, 2008

VIRBAC EXERCISES ITS OPTION FOR A COMMERCIAL LICENCE AGREEMENT TO USE VIVALIS’ EBx® PLATFORM FOR THE PRODUCTION OF SEVERAL VACCINES.

  • 1
  • …
  • 47
  • 48
  • 49
  • 50

Valneva

  • Über uns
  • Produkte
  • F&D
  • Investoren
  • Medien
  • Karriere
Weitere Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Kontakt
© 2023 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

The information collected through these tracking and performance cookies do not identify any individual visitor.
SAVE & ACCEPT